Evidence map›Paper›PMID 40385345›Full record

ArticleAnnals of gastroenterological surgery2025

Impact of gastrectomy on efficacy and safety of second-line chemotherapy patients with advanced gastric cancer: Exploratory analysis of two randomized phase III trials.

Kazuhiro Nishikawa, Wasaburo Koizumi, Akira Tsuburaya, Motoko Suzuki, Satoshi Morita, Kazumasa Fujitani, Yusuke Akamaru, Ken Shimada, Hisashi Hosaka, Ken Nishimura and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of gastroenterological surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Kazuhiro NishikawaCancer Treatment Center OsakaInternational Medical & Science Center, Osaka Keisatsu Hospital Osaka Japan.ORCID https://orcid.org/0000-0003-1213-2732
Wasaburo KoizumiKitasato University Sagamihara Kanagawa Japan.
Akira TsuburayaDepartment of Surgery AOI Nanasawa Rehabilitation Hospital Atsugi Japan.
Motoko SuzukiDepartment of Data Science National Cancer Center Hospital East Chiba Japan.
Satoshi MoritaDepartment of Biomedical Statistics and Bioinformatics Kyoto University Graduate School of Medicine Kyoto Japan.
Kazumasa FujitaniDepartment of Surgery Osaka General Medical Center Osaka Japan.
Yusuke AkamaruDepartment of Surgery Osaka Rosai Hospital Sakai City Osaka Japan.
Ken ShimadaDivision of Medical Oncology Showa University Koto Totosu HospitalDepartment of Internal Medicine Tokyo Japan.
Hisashi HosakaDepartment of Gastroenterology Gunma Prefectural Cancer Center Ohta Japan.
Ken NishimuraDepartment of Oncology Kitasato University Kitasato Institute Hospital Tokyo Japan.
Takaki YoshikawaDepartment of Gastric Surgery The National Hospital Organization National Cancer Center Hospital Tokyo Japan.ORCID https://orcid.org/0000-0003-1936-9484
Toshimasa TsujinakaIzumi City General Hospital Izumi Osaka Japan.
Junichi SakamotoTokai Central Hospital Kakamigahara Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: Second-line chemotherapy (SLC) improves survival in advanced gastric cancer (AGC). Although many patients receiving SLC have undergone gastrectomy, the impact of gastrectomy on SLC remains unclear. Patients and Methods: The objective was to evaluate the impact of gastrectomy on SLC for AGC. A total of 290 eligible patients registered in two randomized phase III trials evaluating SLC for patients with AGC was classified into the prior gastrectomy group (PGG; Results: The PGG had better performance status ( Conclusion: Patients with previous gastrectomy are expected to have better survival outcomes when receiving second-line irinotecan (IRI)-based chemotherapy for AGC.

Indexed as

advanced gastric cancerimpact of gastrectomyirinotecan‐based chemotherapysecond‐line chemotherapy

Identifiers

PMID40385345
PMCPMC12080202

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.